Funding

From the 15th Annual BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York on February 12th, 2013.

Fred Frank, formerly Vice Chairman of both Lehman Brothers Inc. and Peter J. Solomon Company, recently became Vice Chairman of Burrill & Company and Chairman of Burrill Securities, the broker dealer arm of Burrill & Company. He was the first life sciences specialist in investment banking, and the most prolific.

President Obama signed the Jumpstart Our Business Startups (JOBS) Act into law on April 5, 2012. BIO advocated strongly for this new law, which includes several important policies designed to stimulate capital formation for growing businesses.

As an exclusive members-only benefit, BIO offers complimentary One-on-One meeting rooms during the JP Morgan Healthcare Conference, taking place January 7-10, 2013, in San Francisco.

BIO Ventures for Global Health (BVGH) and the Biotechnology Industry Organization (BIO) have collaborated on a new report that builds upon the findings in BVGH’s previous analysis, Developing New Drugs and Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.

Capital formation challenges in the industry have forced many biotech companies to halt projects, lay off staff or shutdown all together. Our analysis shows that the industry is approximately one-quarter smaller than it was in 2008.

BIO believes that the level of support provided by the TDP simply cannot meet the needs of the growing biotech field. As evidence of the project's popularity suggests, Congress should consider extending or expanding the project in order to support American innovation and speed the development of life-saving cures.

The biotech industry is a thriving sector employing 1.3 million Americans in high quality, high paying jobs.

William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth. Mr. Waddill provided testimony today on behalf of BIO at a Senate Committee on Banking, Housing, and Urban Affairs hearing.

Aaron Miscenich, president of the New Orleans BioInnovation Center and chairman of LouisianaBio, discusses the bioscience economic development initiatives.

Congress has the opportunity to help speed lifesaving cures and treatments to patients by removing burdens to innovation in our industry.

There are many reasons to be excited about financing early stage biotech companies. The BIO Investor Forum will assemble the most promising among promising discovery stage companies. 

In this global economy, nearly every competitor has access to big breakthroughs in technology and to the equipment and capital to produce standardized products, but those regions that possess the human capital, with its insights, competencies, and experience will have the competitive advantage.

Pete Pellerito discusses what is being done to provide the workforce for this broad and growing industry.

Letters, Testimony & Comments

March 16 2012
Dear Majority Leader Reid and Minority Leader McConnell: On behalf of the Biotechnology Industry Organization (BIO) and its more than 1...
March 6 2012
William D. Waddill, Senior Vice President and Chief Financial Officer OncoMed Pharmaceuticals highlights the importance of capital...
December 1 2011
On December 1, BIO submitted written testimony to the Senate Committee on Banking, Housing, and Urban Affairs on the importance of...
May 17 2011
Dear Chairman Frelinghuysen and Ranking Member Visclosky: On behalf of the Biotechnology Industry Organization (BIO), I am writing to...
May 12 2011
Dear Chairman Kingston and Ranking Member Farr: On behalf of the Biotechnology Industry Organization (BIO), I am writing to encourage...

Press Releases

June 14 2012
WASHINGTON, DC (June 12, 2012) – The Biotechnology Industry Organization (BIO) announced today that New Jersey...
June 6 2012
Washington, DC and New York, NY, Wednesday, June 6, 2012 -The 4th Annual Scientific American Worldview Report and...
December 6 2011
Washington, DC (December 6, 2011) – The Biotechnology Industry Organization (BIO) announces program topics...
November 16 2011
Self-Funding Program Supported by Leading Biotech Trade Associations WASHINGTON, D.C. (November 16, 2011)...
November 2 2011
Washington, DC (November 2, 2011) – The Biotechnology Industry Organization (BIO) strongly supports the Small...